Sugar and fat - that's where it's at: Metabolic changes in tumors

Breast Cancer Research

Volumn 10, Issue 1, 2008, Pages

  Young, Christian D ^a   Anderson, Steven M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAT; GLUCOSE; LACTATE DEHYDROGENASE; NUCLEAR PROTEIN; PROTEIN KINASE B; THRSP PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

BREAST TUMOR; FEMALE; GLYCOLYSIS; HUMAN; LIPID METABOLISM; METABOLISM; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FATS; FEMALE; GENES, P53; GLUCOSE; GLYCOLYSIS; HUMANS; L-LACTATE DEHYDROGENASE; LIPID METABOLISM; MITOCHONDRIA; NUCLEAR PROTEINS; OXIDATIVE PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TRANSCRIPTION FACTORS;

EID: 44849137874     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1852     Document Type: Review

References (71)

1. Warburg O. The Metabolism of Tumors 1930, London: Constable.
2. Pasteur L. Experiences et vues nouvelles sur la nature des fermentations. Comp Rend Acad Sci 1861, 52:1260-1264.
3. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314. 10.1126/science.123.3191.309, 13298683.
4. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CV, Semenza GL. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of c-myc activity. Cancer Cell 2007, 11:407-420. 10.1016/j.ccr.2007.04.001, 17482131.
5. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabolism 2006, 3:187-197. 10.1016/j.cmet.2006.01.012, 16517406.
6. Kim J, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism 2006, 3:177-185. 10.1016/j.cmet.2006.02.002, 16517405.
7. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002, 64:993-998. 10.1016/S0006-2952(02)01168-1, 12213597.
8. Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, Laughner E, Ravi R, Simons J, Taghavi P, Zhong H. 'The metabolism of tumours': 70 years later. Novartis Found Symp 2001, 240:251-260.
9. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129:465-472. 10.1016/j.cell.2007.04.019, 17482542.
10. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007, 17:71-77. 10.1016/j.gde.2006.12.006, 17208433.
11. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007, 12:108-113. 10.1016/j.ccr.2007.07.006, 17692803.
12. LUM JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC, Thompson CB. The transcription factor HIF-1α plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 2007, 21:1037-1049. 1855230, 17437992, 10.1101/gad.1529107.
13. Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DHS. 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. J Nucl Med 2005, 46:1455-1459.
14. Fueger B, Weber W, Quon A, Crawford T, Allen-Auerbach M, Halpern B, Ratib O, Phelps M, Czernin J. Performance of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 2005, 7:369-376. 10.1007/s11307-005-0013-4, 16220355.
15. Czernin J, Phelps ME. Positron emission tomography scanning: current and Future applications. Ann Rev Med 2002, 53:89-112. 10.1146/annurev.med.53.082901.104028, 11818465.
16. Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, Valk PE, Czernin J. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 2001, 42:1334-1337.
17. Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, Ortega AD, Berrendero JR, Pozo-Rodriguez F, Lopez-Encuentra A, Ballestin C, Cuezva JM. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 2007, 67:9013-9017. 17909002, 10.1158/0008-5472.CAN-07-1678.
18. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64:3892-3899. 15172999, 10.1158/0008-5472.CAN-03-2904.
19. Hill MM, Clark SF, Tucker DF, Birnbaum MJ, James DE, Macaulay SL. A role for protein kinase Bbeta/Akt2 in insulin-stimulated GLUT4 translocation in adipocytes. Mol Cell Biol 1999, 11:7771-7781.
20. Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 2001, 21:5899-5912. 87309, 11486029, 10.1128/MCB.21.17.5899-5912.2001.
21. Edinger A, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 2002, 13:2276-2288. 117312, 12134068, 10.1091/mbc.01-12-0584.
22. Bentley J, Itchayanan D, Barnes K, McIntosh E, Tang X, Downes CP, Holman GD, Whetton AD, Owen-Lynch PJ, Baldwin SA. Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface. J Biol Chem 2003, 278:39337-39348. 10.1074/jbc.M305689200, 12869574.
23. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003, 23:7315-7328. 230333, 14517300, 10.1128/MCB.23.20.7315-7328.2003.
24. Boxer RB, Stairs DB, Dugan KD, Notarfrancesco KL, Portocarrero CP, Keister BA, Belka GK, Cho H, Rathmell JC, Thompson CB, Birnbaum MJ, Chodosh LA. Isoform-specific requirement for Akt1 in the developmental regulation of cellular metabolism during lactation. Cell Metab 2006, 4:475-490. 10.1016/j.cmet.2006.10.011, 17141631.
25. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007, 7:389-397. 10.1038/nrc2127, 17446858.
26. Cantley LC, Neel BG. New insights into tumor supression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999, 96:4240-4245. 33561, 10200246, 10.1073/pnas.96.8.4240.
27. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5:921-929. 10.1038/nrc1753, 16341083.
28. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444. 10.1038/nature05933, 17611497.
29. Godoy A, Ulloa V, Rodriguez F, Reincke K, Yanez AJ, Garcia MDLA, Medina RA, Carrasco M, Barberis S, Castro T, martinez F, Koch X, Vera JC, Poblete MT, Figueroa CD, Peruzzo B, Perez F, Nualart F. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: Ultrastructural localization of GLUT1 and GLUT5 in breast tumor tisues. J Cell Physiol 2006, 207:614-627. 10.1002/jcp.20606, 16523487.
30. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 2006, 25:4683-4696. 16892082, 10.1038/sj.onc.1209595.
31. Majewski N, Nogueira V, Robey RB, Hay N. Akt Inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol 2004, 24:730-740. 343797, 14701745, 10.1128/MCB.24.2.730-740.2004.
32. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB, Hay N. Hexokinase-mitochondria interaction mediated by Akt Is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 2004, 16:819-830. 10.1016/j.molcel.2004.11.014, 15574336.
33. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001, 15:1406-1418. 312709, 11390360, 10.1101/gad.889901.
34. Berwick DC, Hers I, Heesom KJ, Moule SK, Tavare JM. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem 2002, 277:33895-33900. 10.1074/jbc.M204681200, 12107176.
35. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005, 24:6314-6322. 10.1038/sj.onc.1208773, 16007201.
36. DeBerardinis RJ, Lum JJ, Thompson CB. Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth. J Biol Chem 2006, 281:37372-37380. 10.1074/jbc.M608372200, 17030509.
37. Pelicano H, Xu R, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 2006, 175:913-923. 2064701, 17158952, 10.1083/jcb.200512100.
38. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408:307-310. 10.1038/35042675, 11099028.
39. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005, 18:283-293. 10.1016/j.molcel.2005.03.027, 15866171.
40. Carling D. AMPK. Curr Biol 2004, 14:R220. 10.1016/j.cub.2004.02.048, 15043827.
41. Carling D. The AMP-activated protein kinase cascade: a unifying system for energy control. Trends Biochem Sci 2004, 29:18-24. 10.1016/j.tibs.2003.11.005, 14729328.
42. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci 2005, 102:8204-8209. 1142118, 15928081, 10.1073/pnas.0502857102.
43. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. p53 Regulates mitochondrial respiration. Science 2006, 312:1650-1653. 10.1126/science.1126863, 16728594.
44. Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120. 10.1016/j.cell.2006.05.036, 16839880.
45. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005, 65:177-185.
46. Engel M, Mazurek S, Eigenbrodt E, Welter C. Phosphoglycerate mutase-derived polypeptide inhibits glycolytic flux and induces cell growth arrest in tumor cell lines. J Biol Chem 2004, 279:35803-35812. 10.1074/jbc.M402768200, 15181008.
47. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9:425-434. 10.1016/j.ccr.2006.04.023, 16766262.
48. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, laFavera R, Dang CV. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997, 94:6658-6663. 21214, 9192621, 10.1073/pnas.94.13.6658.
49. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999, 24:68-72. 10.1016/S0968-0004(98)01344-9, 10098401.
50. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005, 15:300-308. 10.1016/j.semcancer.2005.04.009, 15908230.
51. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue IV: a study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 1953, 13:27-29.
52. Ookhtens M, Kannan R, Lyon I, Baker N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol Regul Integr Comp Physiol 1984, 247:R146-R153.
53. Sabine JR, Abraham S, Chaikoff IL. Control of lipid metabolism in hepatomas: insensitivity of rate of fatty acid and cholesterol synthesis by mouse hepatome BW7756 to fasting and to feedback control. Cancer Res 1967, 27:793-799.
54. Szutowicz A, Kwiatkowski J, Angielski S. Lipogenic and glycolytic anzyme activites in carcinoma and nonmalignant diseases of the human breast. Br J Cancer 1979, 39:681-687.
55. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000, 16:202-208. 10.1016/S0899-9007(99)00266-X, 10705076.
56. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR. Fatty acid synthesis: a potential selctive taret for antineoplastic therapy. Proc Natl Acad Sci USA 1994, 91:6379-6383. 44205, 8022791, 10.1073/pnas.91.14.6379.
57. Swinnen JV, Vanderhoydonc F, Elgamal AA, Eelen M, Vercaeren I, Joniau S, Van Poppel H, Baert L, Goossens K, Heyns W, Verhovoeven G. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 2000, 88:176-179. 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3, 11004665.
58. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 2003, 1:707-715.
59. Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, Van de Sande T, Heemers H, Heyns W, Verhoeven G. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 2003, 302:898-903. 10.1016/S0006-291X(03)00265-1, 12646257.
60. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 2003, 63:3799-3804.
61. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-α gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005, 65:6719-6725. 10.1158/0008-5472.CAN-05-0571, 16061653.
62. Kuhajda FP, Piantadosi S, Pasternack GR. Haptoglobin-related protein (Hpr) epitopes in breast cacner as a predictor of recurrance of the disease. N Engl J Med 1989, 321:636-641.
63. Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gendreau V, Zuo D, Papavasiliou V, Lavoie C, Turpin J, Cianflone K, Huntsman DG, Muller WJ. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development. Mol Cell Biol 2007, 27:6361-6371. 2099621, 17636013, 10.1128/MCB.00686-07.
64. Seelig S, Liaw C, Towle H, Oppenheimer J. Thyroid hormone attenuates and augments hepatic gene expression at a pre-translactional level. Proc Natl Acad Sci USA 1981, 78:4733-4737. 320237, 6946422, 10.1073/pnas.78.8.4733.
65. Kinlaw WB, Tron P, Friedmann AS. Nuclear localization and hepatic zonation of rat 'spot 14' protein: immunohistochemical investigation employing anti-fusion protein antibodies. Endocrinology 1992, 131:3120-3122. 10.1210/en.131.6.3120, 1446647.
66. Kinlaw WB, Church JL, Harmon J, Mariash CN. Direct evidence for a role of the 'Spot 14' protein in the regulation of lipid synthesis. J Biol Chem 1995, 270:16615-16618. 10.1074/jbc.270.28.16615, 7622469.
67. Zhu Q, Anderson GW, Mucha GT, Parks EJ, Metkowski JK, Mariash CN. The Spot 14 protein is required for de novo lipid synthesis in the lactating mammary gland. Endocrinology 2005, 146:3343-3350. 10.1210/en.2005-0204, 15890771.
68. Schwertfeger KL, McManaman JL, Palmer CA, Neville MC, Anderson SM. Expression of constitutively activated Akt in the mammary gland leads to excess lipid synthesis during pregnancy and lactation. J Lipid Res 2003, 44:1100-1112. 10.1194/jlr.M300045-JLR200, 12700340.
69. Sundqvist A, goechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW, Ericsson J. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCFFbw7. Cell Metab 2005, 1:379-391. 10.1016/j.cmet.2005.04.010, 16054087.
70. Wendy AW, Gary NS, Peter MM, Bernard FC, Jennifer JG, William BK. Expression of Spot 14 (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker. Breast Cancer Res Treat 2006, 98:231-240. 10.1007/s10549-005-9154-z, 16552628.
71. Kinlaw WB, Quinn JL, Wells WA, Roser-Jones C, Moncur JT. Spot 14: a marker of aggressive breast cancer and a potential therapeutic target. Endocrinology 2006, 147:4048-4055. 10.1210/en.2006-0463, 16809441.